ReviewClinical rheumatology2026
Autologous hematopoietic stem cell transplantation in a patient with rheumatoid arthritis and multiple myeloma: a case-based narrative literature review.
Review in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Rheumatoid arthritis (RA) and multiple myeloma (MM) are rare coexisting conditions that present diagnostic and therapeutic challenges, and while autologous hematopoietic stem cell transplantation (auto-HSCT) is standard for MM, its effect on concomitant RA remains unclear. We report a 50-year-old woman with a 10-year history of RA who developed IgG-κ MM and underwent auto-HSCT following VRD induction and high-dose melphalan conditioning. Serial assessments showed that MM response deepened from partial remission to very good partial remission, with M protein declining and the free light chain ratio normalizing, while RA activity markedly improved-rheumatoid factor decreased from 67.8 to 5.5 IU/mL and DAS28-ESR dropped from 4.33 to 2.25, with complete resolution of joint symptoms and no severe transplant-related complications. A review of the relevant literature supports these findings, suggesting that auto-HSCT may be a safe and effective strategy for simultaneously managing both diseases, although long-term follow-up is necessary to confirm the durability of remission.
Indexed as
Identifiers
42711632What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.